C-aryl glucoside derivative, preparation method therefor, and use thereof

1. A compound represented by the following general formula (I):

wherein:

X is O or S;

each of R 1 and R 2 is independently hydrogen, —OH, —SH, —NH 2 , —NO 2 , —CN, —COH, —COOH, —CONH 2 , halogen, C 1 -C 4 alkyl, —O—C 1 -C 4 alkyl, —S—C 1 -C 4 alkyl, —SO—C 1 -C 4 alkyl, —SO 2 —C 1 -C 4 alkyl, —CO—C 1 -C 4 alkyl, —CO 2 —C 1 -C 4 alkyl, —CONH—C 1 -C 4 alkyl, —C≡C—C 1 -C 4 alkyl, —NHSO 2 —C 1 -C 4 alkyl, —NHCO—C 1 -C 4 alkyl or —C 3 -C 6 cycloalkyl;

R 3 is hydrogen, —OH, —SH, —NH 2 , —NO 2 , —CN, —COH, —COOH, —CONH 2 , halogen, —C 1 -C 4 alkyl, —O—C 1 -C 4 alkyl, —S—C 1 -C 4 alkyl, —CO—C 1 -C 4 alkyl, —CO 2 —C 1 -C 4 alkyl, —CONH—C 1 -C 4 alkyl, an aryl having 1-3 substituents selected from the groups in Group A, a heteroaryl having 1-3 substituents selected from the groups in Group A, a C3-C8cycloalkyl having 1-3 substituents selected from the groups in Group A, a nitrogen-containing saturated heterocyclic group having 1-3 substituents selected from the groups in Group A or a nitrogen-containing partially unsaturated heterocyclic group having 1-3 substituents selected from the groups in Group A, wherein, the group in Group A is selected from the group consisting of: hydrogen, halogen, —OH, —SH, —NH 2 , —NO 2 , —CN, —COH, —COOH, —CONH 2 , C 1 -C 4 alkyl, —O—C 1 -C 4 alkyl, —NH—C 1 -C 4 alkyl, —S—C 1 -C 4 alkyl, —SO 2 —C 1 -C 4 alkyl, —CO—C 1 -C 4 alkyl, —CO 2 —C 1 -C 4 alkyl, —CONH—C 1 -C 4 alkyl, —CONH—C 3 -C 6 cycloalkyl, —C 1 -C 4 alkyl-OH, -aryl, —O-aryl, —NH-aryl, —S-aryl, —SO 2 -aryl, —CO-aryl, —CO 2 -aryl, —CONH-aryl, -cycloalkyl, -heteroaryl, -a nitrogen-containing saturated heterocyclic group, —C 1 -C 4 alkyl-a nitrogen-containing saturated heterocyclic group and -a nitrogen-containing partially unsaturated heterocyclic group;

R 4 is —O—R 5 , —S—R 5 , —SO—R 5 , —SO 2 —R 5 , R 5 is —C 1 -C 4 alkyl or —C 3 -C 8 cycloalkyl;

m is 1, 2 or 3; and

n is 1 or 2,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said X is S, R 4 is —S—CH 3 or —SO 2 —CH 3 .

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of said R 1 and R 2 is independently hydrogen, —OH, —NH 2 , —NO 2 , —CN, —COOH, halogen, —C 1 -C 4 alkyl, —O—C 1 -C 4 alkyl or —C 3 -C 6 cycloalkyl, both m and n are 1.

4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein each of said R 1 and R 2 is independently hydrogen, halogen or —C 1 -C 4 alkyl.

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein said R 1 is chloro or methyl, R 2 is hydrogen.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is halogen, an aryl having 1-3 substituents selected from the groups in Group A, a heteroaryl having 1-3 substituents selected from the groups in Group A, a nitrogen-containing saturated heterocyclic group having 1-3 substituents selected from the groups in Group A or a nitrogen-containing partially unsaturated heterocyclic group having 1-3 substituents selected from the groups in Group A, wherein, the group in Group A is selected from the group consisting of: hydrogen, halogen, —OH, —NH 2 , —NO 2 , —COH, —COOH, C 1 -C 4 alkyl, —O—C 1 -C 4 alkyl, —S—C 1 -C 4 alkyl, —CONH—C 3 -C 6 cycloalkyl, —C 1 -C 4 alkyl-OH and —C 1 -C 4 alkyl-a nitrogen-containing saturated heterocyclic group.

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein said R 3 is halogen.

8. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein said R 3 is a phenyl having 1-3 substituents selected from the groups in Group A, wherein, the group in Group A is selected from the group consisting of: hydrogen, halogen, —OH, —NH 2 , —NO 2 , —COH, —COOH, —C 1 -C 4 alkyl, —O—C 1 -C 4 alkyl, —S—C 1 -C 4 alkyl, —CONH—C 3 -C 6 cycloalkyl, —C 1 -C 4 alkyl-OH and —C 1 -C 4 alkyl-a nitrogen-containing saturated heterocyclic group.

9. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein said R 3 is a pyridyl having 1-3 substituents selected from the groups in Group A, wherein, the group in Group A is selected from the group consisting of: hydrogen, halogen, —OH, —NH 2 , —NO 2 , —COH, —COOH, —C 1 -C 4 alkyl, —O—C 1 -C 4 alkyl, —S—C 1 -C 4 alkyl, —CONH—C 3 -C 6 cycloalkyl, —C 1 -C 4 alkyl-OH and —C 1 -C 4 alkyl-a nitrogen-containing saturated heterocyclic group.

10. The compound of claim 1 , selected from the group of the following compounds:

(2S,3R,4R,5S,6R)-2-[3-((5-(4-fluorophenyl)thienyl)-2-methylene)-4-chloro-phenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-fluorophenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-fluoropyridyl)thienyl)-2-methylene)-4-chloro-phenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-chloro)thienyl)-2-methylene)-4-chloro-phenyl)-6-methylthio-tetrahydropyran-3,4,5-triol,

(2S,3R,4R,5S,6R)-2-[3-((5-(4-bromo)thienyl)-2-methylene)-4-methyl-phenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(3,4,5-trifluorophenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(3,4-difluorophenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-methoxyphenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(3-cynaophenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(2-formylphenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(3-formylphenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-((4-methylpiperazin-1-yl)methyl)phenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-3-(morpholinylmethyl)phenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-carboxylphenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-N-cyclopropylbenzamide)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-methylthiophenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(2-furyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-hydroxymethylphenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(3-aminophenyl)thienyl)-2-methylene)-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol;

(2S,3R,4R,5S,6R)-2-[3-((5-(4-fluorophenyl)thienyl)-2-methylene)-2-methoxy-4-methylphenyl)-6-methylthio-tetrahydropyran-3,4,5-triol; and

(2S,3R,4R,5S,6R)-2-[3-((5-(4-fluorophenyl)thienyl)-2-methylene)-4-chloro-phenyl)-6-methylsulfonyl-tetrahydropyran-3,4,5-triol, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 1 and R 2 is independently selected from —OH, —SH, —NH 2 , —NO 2 , —CN, —COH, —COOH, —CONH 2 , halogen, C 1 -C 4 alkyl, —O—C 1 -C 4 alkyl, —S—C 1 -C 4 alkyl, —SO—C 1 -C 4 alkyl, —SO 2 —C 1 -C 4 alkyl, —CO—C 1 -C 4 alkyl, —CO 2 —C 1 -C 4 alkyl, —CONH—C 1 -C 4 alkyl, —C≡C—C 1 -C 4 alkyl, —NHSO 2 —C 1 -C 4 alkyl, —NHCO—C 1 -C 4 alkyl, and —C 3 -C 6 cycloalkyl.

12. A pharmaceutical composition, which contains the compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

13. A process for preparing the compound of general formula (I) according to claim 1 , which comprises the steps of:

herein, X, R 1 , R 2 , R 3 , R 4 , m and n are defined as claim 1 , (3aS,5R,6S,6aS)-[6-hydroxy-2,2-dimethyl-tetrahydrofuro[3,2-d][1,3]-dioxol-5-yl]-(morpholino)methanone I(g) is used as starting material, to which is added a halide of formula I(a), and then an alcohol I(b) is obtained; I(b) is treated with an alcohol and water in the presence of an acid, and acetylizad with acetic anhydride in the presence of an organic base to obtain a compound I(c); I(c) is added to an acetic acid solution containing bromide hydrogen to conduct the reaction to obtain a compound I(d), which is reacted with a nucleophilic reagent alkoxide, mercaptide or mercaptan without separation and purification to obtain a compound I(e) directly (if R 4 =—O—R 5 , —S—R 5 ) or after the oxidation (if R 4 =—SO—R 5 or —SO 2 —R 5 ); and the acetyl of the saccharide moiety in the compound I(e) is hydrolyzed conventionally to obtain the target compound I.

14. A method for treating diabetes mellitus, the method comprising administering to a patient in need thereof a compound according to claim 1 or a pharmaceutically acceptable salt thereof.